Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion
Phase 2 small_molecule active
Quick answer
Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion for HNSCC, metastatic deficient mismatch repair (dMMR)/MSI-high (MSI-H) tumors, irresectable or metastatic melanoma, locally advanced or metastatic solid tumor is a Phase 2 program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Disc Medicine
- Indication
- HNSCC, metastatic deficient mismatch repair (dMMR)/MSI-high (MSI-H) tumors, irresectable or metastatic melanoma, locally advanced or metastatic solid tumor
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active